Return to Clinical Trials

Phase II Intravenous Administration Sarcomas Trial - United States

In June 2009, Oncolytics announced positive interim results in its completed U.S. Phase II intravenous administration trial for patients with sarcomas metastatic to the lung. Interim results demonstrated that 42% of patients achieved stable disease for more than 16 weeks, including one patients who had stable disease for more than 80 weeks.

The primary objective of the trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN® in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN® is given intravenously to patients at a dose of 3x10¹⁰ TCID₅₀ for five consecutive days. 52 patients were enrolled in the study.

See related press releases and documents:

November 6, 2009 - A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung

A Phase II Study of Intravenous REOLYSIN (Wild-type reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung

Interim Phase II Sarcoma Results

November 6, 2009 - Oncolytics Biotech® Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting

June 1, 2009 - Oncolytics Biotech® Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting

May 12, 2009 - Oncolytics® Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study

November 6, 2008 - Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN® Phase II Sarcoma Trial Data

June 2, 2008 - Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting

June 27, 2007 - Oncolytics Biotech Inc. Commences Patient Enrolment in U.S. Phase II Sarcoma Clinical Trial

April 11, 2007 - Oncolytics Biotech Inc. Proceeds to Initiate U.S. Phase II Sarcoma Clinical Trial